SOPHiA GENETICS SA (NASDAQ:SOPH) Stock Has Average Target Price of $10.00

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) have earned a consensus recommendation of “Hold” from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $10.00.

SOPH has been the topic of several recent analyst reports. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, October 15th. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of SOPHiA GENETICS in a research report on Monday, October 12th. Finally, BTIG Research boosted their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th.

Insider Buying and Selling at SOPHiA GENETICS

In other SOPHiA GENETICS news, insider Zhenyu Xu sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 13th. The stock was sold at an average price of $7.18, for a total value of $28,720.00. Following the transaction, the insider directly owned 541,493 shares of the company’s stock, valued at approximately $3,887,919.74. The trade was a 0.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Chairman Jurgi Camblong sold 8,500 shares of the stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $7.26, for a total value of $61,710.00. Following the transaction, the chairman owned 3,387,150 shares in the company, valued at $24,590,709. The trade was a 0.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 250,662 shares of company stock valued at $1,942,499 over the last ninety days. Insiders own 4.88% of the company’s stock.

Institutional Trading of SOPHiA GENETICS

Several hedge funds have recently modified their holdings of SOPH. Maven Securities LTD acquired a new position in shares of SOPHiA GENETICS during the 2nd quarter valued at $866,000. AWM Investment Company Inc. acquired a new stake in SOPHiA GENETICS in the second quarter worth $9,809,000. Sei Investments Co. acquired a new stake in SOPHiA GENETICS in the first quarter worth $1,772,000. Sowell Financial Services LLC bought a new stake in SOPHiA GENETICS in the third quarter valued at $2,865,000. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in SOPHiA GENETICS in the second quarter valued at $567,000. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Trading Down 4.3%

NASDAQ:SOPH opened at $7.63 on Friday. The firm’s fifty day moving average is $7.87 and its 200-day moving average is $5.95. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. SOPHiA GENETICS has a 52 week low of $3.83 and a 52 week high of $8.98. The firm has a market cap of $640.12 million, a P/E ratio of -6.63 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. The firm had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. Equities analysts expect that SOPHiA GENETICS will post -0.77 earnings per share for the current year.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a healthcare technology company that develops data-driven solutions for genomic medicine. Its cloud-based platform uses artificial intelligence, machine learning and advanced analytics to help healthcare organizations analyze and interpret complex biological and clinical data.

The company’s primary offering, the SOPHiA DDM platform, supports next-generation sequencing workflows, including data management, quality control, genomic analysis, variant interpretation and reporting.